Benitec Biopharma Limited
Patent Applications and Registrations
Patent applications and USPTO patent grants for Benitec Biopharma Limited.The latest application filed is for "methods for treating oculopharyngeal muscular dystrophy (opmd)".
- Benitec Biopharma Limited - Hayward CA US
- Benitec Biopharma Limited - North Sydney N/A AU
- Benitec Biopharma Limited - North Sydney, New South Wales AU
- Benitec Biopharma Limited - New South Wales N/A AU
- BENITEC BIOPHARMA LIMITED - Balmain, New South Wales N/A AU
- BENITEC BIOPHARMA LIMITED - Balmain AU
| Patent | Date |
|---|---|
| Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD) App 20220106594 - Strings-Ufombah; Vanessa ; et al. | 2022-04-07 |
| Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof Grant 11,234,994 - Suhy , et al. February 1, 2 | 2022-02-01 |
| Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof Grant 11,142,765 - Strings-Ufombah , et al. October 12, 2 | 2021-10-12 |
| Reagents For Treatment Of Hepatitis B Virus (hbv) Infection And Use Thereof App 20210177885 - MAO; TIN ; et al. | 2021-06-17 |
| Reagents for treatment of hepatitis B virus (HBV) infection and use thereof Grant 10,898,505 - Mao , et al. January 26, 2 | 2021-01-26 |
| Adeno-Associated Virus (AAV) with Modified Phospholipase Domain App 20200190481 - Strings-Ufombah; Vanessa ; et al. | 2020-06-18 |
| Reagents For Treatment Of Oculopharyngeal Muscular Dystrophy (opmd) And Use Thereof App 20200138849 - SUHY; David ; et al. | 2020-05-07 |
| Reagents For Treatment Of Hepatitis B Virus (hbv) Infection And Use Thereof App 20190338285 - MAO; Tin ; et al. | 2019-11-07 |
| Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof App 20190330629 - Strings-Ufombah; Vanessa ; et al. | 2019-10-31 |
| REAGENTS FOR PRODUCING T-CELLS WITH NON-FUNCTIONAL T-CELL RECEPTORS (TCRs) COMPOSITIONS COMPRISING SAME AND USE THEREOF App 20190309307 - GARCIA; Patty Bertha ; et al. | 2019-10-10 |
| Reagents For Treatment Of Hepatitis B Virus (hbv) Infection And Use Thereof App 20190022124 - MAO; Tin ; et al. | 2019-01-24 |
| Age-related Macular Degeneration Treatment App 20180320180 - SUHY; David ; et al. | 2018-11-08 |
| Age-related macular degeneration treatment Grant 10,000,753 - Suhy , et al. June 19, 2 | 2018-06-19 |
| HBV treatment Grant 9,790,502 - Graham , et al. October 17, 2 | 2017-10-17 |
| Hbv Treatment App 20170002356 - Graham; Michael Wayne ; et al. | 2017-01-05 |
| Pain treatment Grant 9,518,260 - French , et al. December 13, 2 | 2016-12-13 |
| HBV treatment Grant 9,410,154 - Graham , et al. August 9, 2 | 2016-08-09 |
| Age-related Macular Degeneration Treatment App 20160145611 - SUHY; David ; et al. | 2016-05-26 |
| Hbv Treatment App 20150344885 - Graham; Michael Wayne ; et al. | 2015-12-03 |
| HBV treatment Grant 9,080,174 - Graham , et al. July 14, 2 | 2015-07-14 |
| Pain Treatment App 20150045411 - French; Peter William ; et al. | 2015-02-12 |
| Minigene expression cassette Grant 8,129,510 - Kay , et al. March 6, 2 | 2012-03-06 |
| NCAGE Code | Z0QM2 | BENITEC BIOPHARMA LIMITED |
| CAGE Code | Z0QM2 | BENITEC BIOPHARMA LIMITED |
| SEC | 0001552795 | Benitec Biopharma LTD/ADR |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 